Close

Seattle Genetics (SGEN) Announces FDA Granted Breakthrough Therapy Designation to ADCETRIS for Frontline Peripheral T-Cell Lymphomas

Go back to Seattle Genetics (SGEN) Announces FDA Granted Breakthrough Therapy Designation to ADCETRIS for Frontline Peripheral T-Cell Lymphomas
Seattle Genetics Inc /wa (NASDAQ: SGEN) Delayed: 228.74 --0 (-0%)
Previous Close $228.74    52 Week High $75.36 
Open $228.74    52 Week Low $26.02 
Day High $228.74    P/E N/A 
Day Low $228.74    EPS $-0.51 
Volume